Aug 2026· Journal of Applied Pharmaceutical Sciences· Vol 16, pp. 941 - 952· 0 citations· 55 references
TL;DR
Artificial neural networks, ensemble models, and support vector machines may improve warfarin dose prediction compared with conventional methods, but the current evidence should be interpreted cautiously.
Abstract
Warfarin therapy is complicated by its narrow therapeutic index and significant inter-individual variability. This study aimed to systematically review the performance of machine learning (ML) for predicting warfarin doses in clinical settings, compared with conventional methods, and to assess the quality of evidence. We searched PubMed, Embase, and Web of Science until December, 2024, and included studies developing ML models for warfarin dosing in clinical settings. The performance metrics of ML models were evaluated using predictive accuracy, model fit, and clinical utility. Risks of bias were assessed using the Prediction Model Risk of Bias Assessment Tool. Thirty-five studies were included. In terms of ML models, the majority of included studies evaluated artificial neural networks (n = 24), followed by ensemble models (n = 19), and support vector machines (n = 18). Regarding performance, ML models demonstrated superiority across all three metrics: predictive accuracy (16 of 18 studies), model fit (5 of 7 studies), and INR-related clinical utility (all 4 studies). A high risk of bias was identified in 94% of studies, mainly due to analysis-domain limitations, including missing-data handling, insufficient events per predictor, unclear predictor selection, and limited external validation. In conclusion, ML-based approaches may improve warfarin dose prediction compared with conventional methods, but the current evidence should be interpreted cautiously. Future studies should prioritize transparent reporting, robust model development, external validation, and clinically relevant outcomes before these models can be recommended for routine clinical implementation.
ML models show promising discriminative performance for DKD prediction, but the evidence is severely limited by high heterogeneity, lack of external validation and reporting of calibration metrics, and poor methodological transparency.
Objectives This study aimed to systematically evaluate the predictive performance of machine learning (ML)–based models for predicting hypoglycemia in Chinese patients with diabetes. Methods We systematically searched PubMed, Embase, Web of Science, the Cochrane Library, CINAHL, CNKI, and Wanfang databases from incepti...
Jin-Hua Yan, Yan-Ping Song, Y. Du et al.· PLoS ONE· 0 citations
INTRODUCTION
Machine learning (ML) models have been increasingly applied to support the diagnosis of bloodstream infections (BSI), particularly through the analysis of large routinely collected healthcare datasets. However, it remains uncertain whether large sample sizes alone are sufficient to achieve high diagnostic...
D. Giacobbe, Elena Ceccardi, M. Muccio et al.· Infectious Disease and Thera...· 0 citations
AI/ML models show promise for predicting CV adverse events in patients with cancer; however, clinical applicability is constrained by insufficient preprocessing transparency, limited external validation, and inadequate calibration reporting.
Li-Wei Wu, Minh-Anh Le-Dang, B. Okoye et al.· Expert review of pharmacoeco...· 0 citations
Abstract Aims Cancer therapy-related cardiac dysfunction (CTRCD) is a prevalent complication with adverse clinical implications. Guidelines have emphasized the need for reliable baseline risk prediction to guide prevention strategies. While machine learning (ML) has shown promise in cardiovascular medicine, the readine...
M. Andres, Vijay Maharahan, Alexandra Pons Rivarola et al.· European Heart Journal - Dig...· 0 citations